Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT04658862 | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder(SunRISe-2) | active not recruiting | Phase 3 | 518 | Janssen Research & Development, LLC |
| 25 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)(SunRISe-3) | active not recruiting | Phase 3 | 1,135 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05538663 | Intravesical BCG vs GEMDOCE in NMIBC(BRIDGE) | active not recruiting | Phase 3 | 870 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05704244 | Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) | active not recruiting | Phase 3 | 25 | Ferring PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03244384 | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer(AMBASSADOR) | active not recruiting | Phase 3 | 739 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03775265 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 475 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05776758 | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt | active not recruiting | Phase 3 | 236 | Regina Elena Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03732677 | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC(NIAGARA) | active not recruiting | Phase 3 | 1,063 | AstraZenecaINDUSTRY | 22 | Jul 17, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | active not recruiting | Phase 3 | 367 | CG Oncology, Inc.INDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT03757949 | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | active not recruiting | Phase 3 | 203 | SWOG Cancer Research NetworkNETWORK | 1 | May 4, 2026 | clinicaltrials |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT03091660 | S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 1,000 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials